氨苄西林钠

氨苄西林钠用途

【用途一】
属半合成的广谱青霉素，主要用于青霉素敏感革兰氏阳性球菌、大肠杆菌、变形杆菌、沙门氏菌、痢疾杆菌等治疗
【用途二】
属半合成的广谱青霉素，主要用于革兰阳性球菌、大肠杆菌、变形杆菌、沙门氏菌、痢疾杆菌等的治疗
【用途三】
半合成的青霉素，抗革兰氏阳性及阴性菌。属β-内酰胺酶抗生素，氨基基团链连接到青霉素结构上。属青霉素衍生物，依靠在细菌细胞膜的内层面使转肽酶（transpeptidases）失活抑制细菌细胞壁的合成。

点击显示

氨苄西林钠名称

[ CAS 号 ]:
69-52-3

[ 中文名 ]:
氨苄青霉素钠

[ 英文名 ]:
Ampicillin sodium

[中文别名 ]:

氨苄西林钠

[英文别名 ]:

omnipen-n
Amcill-s
pena/n
Anhypen
XLD AGAR
penialmen
Alppen-N
EINECS 200-708-1
Alpen-n
Cilleral

氨苄西林钠生物活性

[ 描述 ]:

Ampicillin sodium是一种广谱β-内酰胺类抗生素,可对抗多种革兰氏阳性和革兰氏阴性细菌 (bacteria)。

[ 相关类别 ]:

信号通路 >> 抗感染 >> 细菌

研究领域 >> 感染

[ 靶点 ]

Bacterial[1]

[体外研究]

氨苄青霉素以剂量依赖性方式抑制猪源大肠杆菌的生长。氨苄青霉素的有效抑制浓度为2.5 uG/mL [1]。

[体内研究]

氨苄西林在减轻11周龄猪出血性肠炎的症状方面非常有效[1]。氨苄西林在胆汁中产生的最大浓度是血清中的两倍。口服给药后氨苄西林的峰值浓度是门静脉血液中的两倍,高于外周血[2]。氨苄西林提供针对缺血再灌注脑损伤的神经保护作用。氨苄青霉素降低MMP的活性并增加GLT-1的表达水平。氨苄青霉素预处理可显着降低全脑前脑缺血后内侧海马细胞死亡[3]。

[动物实验]

小鼠：将氨苄青霉素溶于生理盐水中。用氟烷麻醉雄性C57BL / 6小鼠，并进行双侧颈总动脉闭塞40分钟。在短暂的前脑缺血之前，每天施用氨苄青霉素（200mg / kg，腹膜内[ip]）或青霉素G（6,000U / kg或20,000U / kg，ip），持续5天。在对照动物中，以相同的体积和时间表给予盐水[3]。

[参考文献]

[1]. Chopra SL, et al. Effect of Ampicillin on E. Coli of Swine Origin. Can J Comp Med Vet Sci. 1963 Sep;27(9):223-7.

[2]. Lund B, et al. Ampicillin in portal and peripheral blood and bile after oral administration of ampicillin andpivampicillin. Eur J Clin Pharmacol. 1974;7(2):133-5.

[3]. Lee KE, et al. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.

[相关活性小分子]

氨苄西林钠物理化学性质

[ 沸点 ]:
683.9ºC at 760 mmHg

[ 熔点 ]:
215 °C (dec.)(lit.)

[ 分子式 ]:
C₁₆H₁₈N₃NaO₄S

[ 分子量 ]:
371.387

[ 精确质量 ]:
371.091583

[ PSA ]:
140.86000

[ LogP ]:
0.01250

[ 外观性状 ]:
白色至灰白色固体

[ 储存条件 ]:
库房通风低温干燥

[ 水溶解性 ]:
H2O: 50 mg/mL, clear, very faintly yellow

氨苄西林钠MSDS

详细MSDS(安全技术说明书)

氨苄西林钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: XH8400000

CHEMICAL NAME :: 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)- 3,3-dimethyl-7-oxo-, sodium salt, D-(-)-

CAS REGISTRY NUMBER :: 69-52-3

LAST UPDATED :: 199510

DATA ITEMS CITED :: 14

MOLECULAR FORMULA :: C16-H18-N3-O4-S.Na

MOLECULAR WEIGHT :: 371.42

WISWESSER LINE NOTATION :: T45 ANV ESTJ CMVYZR& F1 F1 GVQ &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 100 mg/kg/5D

TOXIC EFFECTS :: Gastrointestinal - hypermotility, diarrhea Gastrointestinal - other changes

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,707,1978

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5314 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 18,356,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 7400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 18,185,1971

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5314 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 18,356,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >5314 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 18,356,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5700 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 18,185,1971

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >5314 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 18,356,1962

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2657 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 18,356,1962 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 210 mg/kg/7D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases

REFERENCE :: INJPD2 Indian Journal of Pharmacology. (Dept. of Pharmacology, Baranas Hindu Univ., Varanasi 221 005, India) V.1- 1968(?)- Volume(issue)/page/year: 18,110,1986 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,153,1990 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,153,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,153,1990 TOXICOLOGY REVIEW INTEAG Internist. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1960- Volume(issue)/page/year: 15,7,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3564 No. of Facilities: 549 (estimated) No. of Industries: 2 No. of Occupations: 8 No. of Employees: 23006 (estimated) No. of Female Employees: 18439 (estimated)

点击显示

氨苄西林钠安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H317-H334

[ 警示性声明 ]:
P261-P280-P342 + P311

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R42/43

[ 安全声明 (欧洲) ]:
S22-S36/37-S45-S36-S26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
XH8400000

[ 海关编码 ]:
2941101900

氨苄西林钠上下游产品

氨苄西林钠上游产品

氨苄西林钠下游产品

氨苄西林钠制备

由氨苄青霉素成盐而得：将氨苄青霉素混悬于水中，用氢氧化钠溶液调节pH至9，溶解，过滤。滤液加活性炭脱色、过滤并将滤液在低温干燥，得产品。

点击显示

氨苄西林钠海关

[ 海关编码 ]: 2941101900

氨苄西林钠文献

Glucose recognition proteins for glucose sensing at physiological concentrations and temperatures.

ACS Chem. Biol. 9(7) , 1595-602, (2014)

Advancements in biotechnology have allowed for the preparation of designer proteins with a wide spectrum of unprecedented chemical and physical properties. A variety of chemical and genetic methods ca...

Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement.

Infect. Immun. 83(3) , 1056-67, (2015)

Uropathogenic strains of Escherichia coli (UPEC) are the major cause of bacteremic urinary tract infections. Survival in the bloodstream is associated with different mechanisms that help to resist ser...

Anti-tumor effects of flavonoids from the ethnic medicine Docynia delavayi (Franch.) Schneid. and its possible mechanism.

J. Med. Food 17(7) , 787-94, (2014)

This study investigated the active components and the anti-tumor efficacy and mechanisms of the flavonoids from Docynia delavayi (Franch.) Schneid. (DDS). MTT assay was used to examine the growth inhi...

更多文献

氨苄西林钠

氨苄西林钠用途

氨苄西林钠名称

氨苄西林钠生物活性

氨苄西林钠物理化学性质

氨苄西林钠MSDS

详细MSDS(安全技术说明书)

氨苄西林钠毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

氨苄西林钠安全信息

氨苄西林钠上下游产品

氨苄西林钠上游产品

氨苄西林钠下游产品

氨苄西林钠制备

氨苄西林钠海关

氨苄西林钠文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

相关化合物